Ogier's Cayman Islands team has advised ARYA Sciences Acquisition Corp (ARYA), a special purpose acquisition company sponsored by Perceptive Advisors, LLC, on its business combination with Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies.
The business combination was effected by way of merger and share exchange. None of the ARYA's shareholders redeemed their shares in connection with ARYA's shareholder approval. Proceeds from the transaction were approximately $253 million, which included funds held in ARYA's trust account and certain private investment.
As a result of the business combination, the combined company is now known as Immatics N.V. and its shares currently trade on the Nasdaq Capital Market.
Ogier's team was led by partner Angus Davison and senior associate Michael Robinson.
Angus said: "We are delighted to have worked with ARYA and to have been able to offer our expertise on such a significant transaction."
Originally published July 21, 2020.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
